BMY recap: Amgen Opdivo biosimilar suit, Hengrui licensing

Bristol-Myers Squibb sued Amgen over an Opdivo biosimilar, discussed a potential $15.2B licensing deal with Jiangsu Hengrui Pharma, and reported durable two-year Sotyktu/POETYK results while declaring a $0.63 quarterly dividend.